港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

2,013.425

+25.1691.27%

涨家数：8

跌家数：- -

平家数：- -

市盈率：- -

高：2,061.985

开：2,003.388

低：2,002.667

收：1,988.255

数据加载中...

盘前公告淘金：微芯生物临床试验获FDA受理、华菱线缆中标4.56亿电力新能源项目，千里科技6月新能源车销量增长74.11%

加科思-B(01167)完成泛KRAS抑制剂JAB-23E73 I/IIa期临床试验在美国的首例患者给药

【加科思-B(01167.HK)完成泛KRAS抑制剂JAB-23E73 I/IIa期临床试验在美国的首例患者给药】智通财

中证创新药30指数上涨2.68%，前十大权重包含药明康德等

天津药明康德新药开发有限公司获中国医学科学院阜外医院采购项目

云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验最新阶段性数据，持续展现优异的有效性与安全性

7月1日界面新闻记者获悉赛诺菲将对天演药业进行战略投资并启动双方SAFEbody安全抗体合作框架下的第三个SAFEbod

微芯生物：CS231295临床试验申请获FDA受理

【微芯生物：CS231295临床试验申请获FDA受理】微芯生物公告，公司全资子公司微芯生物科技（美国）有限公司于2025年6月30日收到美国食品药品监督管理局（FDA）的书面回复，自主研发的CS231295关于晚期实体瘤的临床试验申请获得FDA受理。受理号为IND176942，受理日期为2025年6月30日，适应症为晚期实体瘤，申请事项为新药临床试验申请。CS231295作为透脑AuroraB选择性抑制剂，目前全球尚无同类设计的药物进入临床试验阶段。

【药明康德(02359.HK)7月1日斥资2000.8万元回购28.35万股A股】智通财经APP讯，药明康德(02359

药明康德(02359)7月1日斥资2000.8万元回购28.35万股A股

昂利康：目前在研的创新药项目仅有一个

海正药业：收到HS387片临床试验批准通知书

国内CXO爆发！金斯瑞收到2.138亿美元BD款

安科生物：公司AK2024注射液获得药物临床试验批准

安科生物(300009.SZ)：AK2024注射液临床试验获批准

安科生物：AK2024注射液获药物临床试验批准

前药明生物首席技术官周伟昌加入宜联生物

【方达控股(01521.HK)：Yin Zhuan、李轶梵获委任为提名委员会委员】智通财经APP讯，方达控股(01521

方达控股(01521.HK)：Yin Zhuan及李轶梵获委任为提名委员会委员

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1576/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":2013.4248,"timestamp":1751421287142,"preClose":1988.2554,"halted":0,"volume":26444959,"delay":0,"changeRate":0.012659,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":25.169434,"latestTime":"07-02 09:54:48","open":2003.388,"high":2061.985,"low":2002.6665,"amount":613544350,"amplitude":0.029834,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1751428800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1751419800000,1751428800000],[1751432400000,1751443200000]],"pbRate":2.324694,"peRate":11.103367,"turnoverRate":0.002333,"increases":8,"decrements":0,"flats":0,"marketCap":449579056384,"floatMarketCap":186485086592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":2061.985,"amplitude":0.029834,"preClose":1988.2554,"low":2002.6665,"pbRate":"2.324694","latestPrice":2013.4248,"volume":26444959,"delay":0,"open":2003.388,"prevYearClose":1395.7731,"prevWeekClose":1940.106,"prevMonthClose":1988.255,"prevQuarterClose":1988.255,"fiveDayClose":1981.716,"twentyDayClose":1867.131,"sixtyDayClose":1946.117,"secType":"PLATE","market":"HK","turnoverRate":0.002333,"peRate":11.103367,"marketCap":449579056384,"floatMarketCap":186485086592,"timestamp":1751421287142,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":8,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548548839","title":"盘前公告淘金：微芯生物临床试验获FDA受理、华菱线缆中标4.56亿电力新能源项目，千里科技6月新能源车销量增长74.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548548839","media":"金融界","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548548839?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 08:24","pubTimestamp":1751415843,"startTime":"0","endTime":"0","summary":"【重大事项】长春高新：拟授权公司管理层启动境外发行股份并在香港联交所上市模塑科技：获北美知名电动车企外饰件产品项目定点，预计总销售额12.36亿元永茂泰：拟约4.5亿元投建墨西哥汽车零部件智能制造基地中科环保：拟收购贵港环保100%股权及平南环保100%股权众生药业：国内首家环孢素滴眼液（III）仿制及复方托吡卡胺滴眼液获得《药品注册证书》微芯生物：CS231295临床试验申请获FDA受理欣旺达：","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/07/02082451427625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","688321","399941","161028","BK1141","BK0239","BK0264","BK0169","BK1576","BK1583","399417","001208","BK0012","159875","BK0014","000941.SH","03347","BK0224","BK0188","160640","601777","BK0070"],"gpt_icon":0},{"id":"2548836519","title":"加科思-B(01167)完成泛KRAS抑制剂JAB-23E73 I/IIa期临床试验在美国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2548836519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548836519?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 08:01","pubTimestamp":1751414477,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B 发布公告，公司自主研发的泛KRAS抑制剂JAB-23E73在美国完成I/IIa期临床试验首例患者给药。全球每年新增约270万患有KRAS相关突变的肿瘤患者，这突显了该患者群体巨大的未满足医疗需求以及泛KRAS抑制剂可能带来的潜在益处。JAB-23E73对KRAS具有高度选择性，可同时抑制活性及非活性状态的KRAS，且对 HRAS、NRAS无明显抑制。作为一款口服KRAS抑制剂，JAB-23E73在临床前研究中展现出良好的药代动力学特征和显著的抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","01167","BK1161","BK1576","BK1583","BK1574"],"gpt_icon":0},{"id":"2548515836","title":"【加科思-B(01167.HK)完成泛KRAS抑制剂JAB-23E73 I/IIa期临床试验在美国的首例患者给药】智通财","url":"https://stock-news.laohu8.com/highlight/detail?id=2548515836","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548515836?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 08:01","pubTimestamp":1751414477,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1576","BK1574","BK1161","01167","03347","BK1141"],"gpt_icon":0},{"id":"2548004404","title":"中证创新药30指数上涨2.68%，前十大权重包含药明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2548004404","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548004404?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 20:49","pubTimestamp":1751374176,"startTime":"0","endTime":"0","summary":"数据统计显示，中证创新药30指数近一个月下跌0.66%，近三个月上涨7.92%，年至今上涨20.02%。据了解，中证创新药30指数从沪深市场属于创新药行业的上市公司中，选取30只研发投入较高且具备成长特征的上市公司证券作为指数样本，以反映沪深市场较具成长潜力的创新药上市公司证券的整体表现。从中证创新药30指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012056599795ec5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012056599795ec5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320764599.SGD","LU0052750758.USD","LU2045819591.USD","LU0708995583.HKD","LU2125910500.SGD","BK1141","BK1161","02359","LU1046422090.SGD","06978","BK1574","BK1576","LU2242644610.SGD","BK1583"],"gpt_icon":0},{"id":"2548001820","title":"天津药明康德新药开发有限公司获中国医学科学院阜外医院采购项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2548001820","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548001820?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 20:42","pubTimestamp":1751373723,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年6月30日，中国医学科学院阜外医院发布“3kg毒理批次制备服务采购项目单一来源公示”。该项目预算金额为96万元人民币，拟采用单一来源方式采购，拟定唯一供应商为天津药明康德新药开发有限公司。采购单位为中国医学科学院阜外医院，位于北京市西城区北礼士路167号。采购公告由代理机构北京国际贸易有限公司发布，公示期限自2025年7月1日至2025年7月7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701204229953290ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701204229953290ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","LU2045819591.USD","LU2242644610.SGD","LU0052750758.USD","LU0320764599.SGD","LU0708995583.HKD","BK1576","LU2125910500.SGD","BK1583","02359","LU1046422090.SGD"],"gpt_icon":0},{"id":"2548009674","title":"云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验最新阶段性数据，持续展现优异的有效性与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2548009674","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548009674?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 20:15","pubTimestamp":1751372122,"startTime":"0","endTime":"0","summary":"EVER001安全性和耐受性良好，与此前观察结果一致。云顶新耀拥有这款产品用于肾病治疗的全球权益。共有31名经肾脏活检证实的抗PLA2R自身抗体阳性的原发性膜性肾病患者分别入组低剂量组和高剂量组，接受EVER001共36周的治疗。迄今为止，全球尚未有药物获得批准用于原发性膜性肾病的治疗。此外，EVER001的安全性与耐受性良好，相关不良事件多为轻至中度，且为短暂性反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012015389795e1a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012015389795e1a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","BK1161","01952","BK1574","BK1576","BK1583"],"gpt_icon":0},{"id":"2548050600","title":"7月1日界面新闻记者获悉赛诺菲将对天演药业进行战略投资并启动双方SAFEbody安全抗体合作框架下的第三个SAFEbod","url":"https://stock-news.laohu8.com/highlight/detail?id=2548050600","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548050600?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 19:43","pubTimestamp":1751370207,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","0O59.UK","BK1141","BK4213","BK4139","CRC","BK1583","LU0266512127.USD","LU0456854461.SGD","MSS","ADAG","BK1576","BK4113","BK5011"],"gpt_icon":0},{"id":"2548008141","title":"微芯生物：CS231295临床试验申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008141","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008141?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 18:46","pubTimestamp":1751366776,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","03347","BK0239","BK1576","BK1141","688321"],"gpt_icon":0},{"id":"2548008498","title":"【微芯生物：CS231295临床试验申请获FDA受理】微芯生物公告，公司全资子公司微芯生物科技（美国）有限公司于2025年6月30日收到美国食品药品监督管理局（FDA）的书面回复，自主研发的CS231295关于晚期实体瘤的临床试验申请获得FDA受理。受理号为IND176942，受理日期为2025年6月30日，适应症为晚期实体瘤，申请事项为新药临床试验申请。CS231295作为透脑AuroraB选择性抑制剂，目前全球尚无同类设计的药物进入临床试验阶段。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008498","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008498?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 18:42","pubTimestamp":1751366579,"startTime":"0","endTime":"0","summary":"微芯生物公告，公司全资子公司微芯生物科技（美国）有限公司于2025年6月30日收到美国食品药品监督管理局（FDA）的书面回复，自主研发的CS231295关于晚期实体瘤的临床试验申请获得FDA受理。受理号为IND176942，受理日期为2025年6月30日，适应症为晚期实体瘤，申请事项为新药临床试验申请。CS231295作为透脑AuroraB选择性抑制剂，目前全球尚无同类设计的药物进入临床试验阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/01184251418390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","688321","BK1141","BK1576","BK1583","BK0239"],"gpt_icon":0},{"id":"2548008189","title":"【药明康德(02359.HK)7月1日斥资2000.8万元回购28.35万股A股】智通财经APP讯，药明康德(02359","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008189","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008189?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 18:42","pubTimestamp":1751366577,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0708995583.HKD","LU2125910500.SGD","399300","BK0216","LU1046422090.SGD","603259","LU2045819591.USD","LU1997244956.HKD","02359","BK1576","BK1583","LU2488822045.USD","LU1997245177.USD","LU1969619763.USD","LU0456842615.SGD","LU0320764599.SGD","159982","LU2242644610.SGD","LU0052750758.USD","LU2328871848.SGD","LU2495084118.USD","BK1141","LU1997245094.SGD"],"gpt_icon":0},{"id":"2548008181","title":"药明康德(02359)7月1日斥资2000.8万元回购28.35万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008181","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008181?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 18:42","pubTimestamp":1751366577,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年7月1日斥资2000.8万元回购28.35万股A股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2495084118.USD","LU1997245177.USD","LU2045819591.USD","BK0216","LU0456842615.SGD","BK1141","LU1046422090.SGD","02359","LU2328871848.SGD","159982","LU2125910500.SGD","LU1997244956.HKD","LU1969619763.USD","BK1583","603259","399300","LU0320764599.SGD","LU1997245094.SGD","LU2242644610.SGD","LU2488822045.USD","LU0052750758.USD","LU0708995583.HKD","BK1576"],"gpt_icon":0},{"id":"2548120071","title":"昂利康：目前在研的创新药项目仅有一个","url":"https://stock-news.laohu8.com/highlight/detail?id=2548120071","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548120071?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 16:54","pubTimestamp":1751360098,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","BK1576","BK1161","BK1574","BK4008","BK0239","03347","BK1141","BK4585","06978","BK4500","ALK","002940","159992","BK4588"],"gpt_icon":0},{"id":"2548079077","title":"海正药业：收到HS387片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2548079077","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548079077?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 16:43","pubTimestamp":1751359429,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","BK0028","BK0239","03347","CYB","BK0188","600267","BK1576","BK1583","BK1141","CNHmain","MUCmain","UCmain","MCNHmain"],"gpt_icon":0},{"id":"2548027008","title":"国内CXO爆发！金斯瑞收到2.138亿美元BD款","url":"https://stock-news.laohu8.com/highlight/detail?id=2548027008","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548027008?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 15:00","pubTimestamp":1751353259,"startTime":"0","endTime":"0","summary":"6月30日，金斯瑞生物科技发布公吿称，截至2025年6月27日，其控股子公司南京蓬勃及镇江蓬勃依据与礼新医药签订的经重述及修订的许可协议，已累计收到约2.138亿美元（税后）款项。截至本稿截稿时，金斯瑞生物的股价呈现上升态势，涨幅达到了2.07%。金斯瑞的公告证实了其非全资子公司蓬勃生物与礼新医药就抗PD - 1单域抗体全球许可合作所达成的累计回款金额已高达2.138亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701150345a4c84eca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701150345a4c84eca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","01548","HK0000306685.HKD","BK1141","BK1161","BK1574","BK1576","09939","BK1583","HK0000320223.HKD","HK0000320264.USD","BK1515"],"gpt_icon":0},{"id":"2548026298","title":"安科生物：公司AK2024注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026298","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026298?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 12:22","pubTimestamp":1751343754,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK1141","BK1576","BK0070","BK1583","BK0060","300009","03347","BK0042"],"gpt_icon":0},{"id":"2548026595","title":"安科生物(300009.SZ)：AK2024注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026595","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026595?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 11:53","pubTimestamp":1751341998,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司收到国家药品监督管理局下发的关于“AK2024注射液”的《药物临床试验批准通知书》，国家药品监督管理局，同意本品单药在HER2阳性晚期实体瘤中开展临床试验。公告显示，AK2024是通过采用以曲妥珠单抗为基础的功能检测方法筛选出的具有曲妥珠单抗协同抗肿瘤活性的抗HER2抗体，选择性地作用于人表皮生长因子受体-2(HER2)的细胞外部位，其抗原识别表位不同于曲妥珠单抗或帕妥珠单抗结合的表位。临床前研究表明，AK2024可抑制HER2阳性肿瘤细胞的增殖，与曲妥珠单抗有协同药效，且优于帕妥珠单抗的促进曲妥珠单抗的抗肿瘤协同药效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","BK0042","BK0239","300009","BK0070","BK1576","BK0060","BK1583"],"gpt_icon":0},{"id":"2548025006","title":"安科生物：AK2024注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2548025006","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548025006?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 11:52","pubTimestamp":1751341932,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0070","BK1141","BK1576","BK0239","BK1583","BK0060","300009","BK0042","03347"],"gpt_icon":0},{"id":"2548202827","title":"前药明生物首席技术官周伟昌加入宜联生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2548202827","media":"界面","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548202827?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 10:28","pubTimestamp":1751336892,"startTime":"0","endTime":"0","summary":"7月1日，宜联生物宣布，正式聘任周伟昌博士为公司首席技术官（CTO）。公司称，周伟昌在生物医药方面丰富的行业经验将帮助宜联生物加强创新管线的全球化开发进程。此前，周伟昌曾历任药明生物执行董事、首席技术官、全球生物制剂开发及运营总裁等重要职位。在2012年加入药明生物前，其曾在Genzyme Corporation（现为Sanofi的一部分）、PDL BioPharma Inc.和Merck & Co. Inc.等知名机构担任CMC（化学、制造和控制）团队的高级领导职务。（界面新闻记者 陈杨）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701102813a4c7d799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701102813a4c7d799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1589","BK1521","LU0326950275.SGD","LU0320764599.SGD","LU0516423174.USD","LU0708995583.HKD","LU0051755006.USD","LU2039709279.SGD","LU0359202008.SGD","LU0181495838.USD","LU1794554557.SGD","LU0823426480.USD","LU0516422440.USD","LU0856984785.SGD","LU0516422952.EUR","LU0516422366.SGD","LU0979878070.USD","LU0052750758.USD","LU0823426308.USD","LU0327786744.USD","LU1688375341.USD","LU0348735423.USD","LU0819121731.USD","LU1242518857.USD","LU0588546209.SGD","BK1610","LU1720050803.USD","LU0516423091.SGD","LU1242518931.SGD","SG9999002562.SGD","02269","LU0039217434.USD","LU0417516738.SGD","BK1576","LU1880383366.USD","LU0140636845.USD","LU0456846285.SGD","LU0043850808.USD","LU0348825331.USD","LU0417516902.SGD","IE00B0JY6N72.USD","SG9999002463.SGD","LU0359201612.USD","LU0572944931.SGD","LU0456827905.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2547155390","title":"【方达控股(01521.HK)：Yin Zhuan、李轶梵获委任为提名委员会委员】智通财经APP讯，方达控股(01521","url":"https://stock-news.laohu8.com/highlight/detail?id=2547155390","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547155390?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 23:23","pubTimestamp":1751296994,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","01521"],"gpt_icon":0},{"id":"2547013698","title":"方达控股(01521.HK)：Yin Zhuan及李轶梵获委任为提名委员会委员","url":"https://stock-news.laohu8.com/highlight/detail?id=2547013698","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547013698?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 22:47","pubTimestamp":1751294855,"startTime":"0","endTime":"0","summary":"格隆汇6月30日丨方达控股(01521.HK)发布公告，以下董事会提名委员会组成的变动，自2025年6月30日起生效：(a)非执行董事Yin Zhuan已获委任为提名委员会委员；及(b)独立非执行董事李轶梵已获委任为提名委员会委员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/30224751394785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","01521","BK1583","BK1576"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":1,"totalSize":225,"code":"91000000","status":"200"}]}}